ConductScience.org, home

Library / Trial comparisons

FluNG Group vs Fluarix Group: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.1860.1810.191wilsonClinicalTrials.gov
Risk in group 20.1860.1810.192wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.000547-0.007850.00675newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9970.9591.04logClinicalTrials.gov
Odds ratio, group 1 over group 20.9960.951.05logClinicalTrials.gov
Number needed to treat, for one fewer participant with a serious adverse event on FluNG Group than on Fluarix Group1,830from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1FluNG Group
subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
4,07121,893EG000ClinicalTrials.gov
Group 2Fluarix Group
subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
4,06621,802EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, serious adverse eventsClinicalTrials.gov
Time frame
Solicited symptoms: During the 7-day post-vaccination period the first year (2008/2009) and the second year (2009/2010). SAEs: During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)
ClinicalTrials.gov

Trial 8

FieldValueSource
TitleTrial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and OlderClinicalTrials.gov
NCT numberNCT00753272ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsInfluenzaClinicalTrials.gov
InterventionsGSK Bio's influenza vaccine GSK2186877A, Fluarix TMClinicalTrials.gov
Lead sponsorGlaxoSmithKlineClinicalTrials.gov
Results first posted2012-06-19ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00753272?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.